Valuation: BriaCell Therapeutics Corp.

Market Cap 29.89M 26.23M 24.77M 22.58M 42.26M 2.86B 42.56M 296M 115M 1.46B 112M 110M 4.7B P/E 2024
-2.56x
P/E 2025 -0.12x
Enterprise Value 12.02M 10.55M 9.97M 9.08M 17M 1.15B 17.12M 119M 46.19M 589M 45.15M 44.17M 1.89B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.49%
Yield 2024 *
-
Yield 2025 -
09-14 BriaCell Therapeutics Corp Receives Seventh Consecutive Positive DSMB Recommendation For Pivotal Phase 3 Bria-ABC Study Of Bria-IMT Plus Immune Checkpoint Inhibitor CI
09-11 Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer CI
09-08 BriaCell Therapeutics Corp. Expands Pivotal Phase 3 Metastatic Breast Cancer Study To Memorial Sloan Kettering Cancer Center CI
09-01 Certain Common Shares of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
09-01 Certain Warrants of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
09-01 Certain Options of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
09-01 Certain Restricted Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
09-01 Certain Performance Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
08-24 BriaCell Therapeutics Corp. Advances Personalized Melanoma Immunotherapy Vaccine Candidate Bria-MEL+ CI
08-05 BriaCell Gets FDA Approval to Start Phase 1/2a of Prostate Cancer Immunotherapy Study MT
08-05 Briacell Therapeutics Corp Receives Fda Clearance to Initiate Bria-Pros+ Clinical Study in Prostate Cancer CI
07-16 BriaCell Opens First Canadian Site For Phase 3 Metastatic Breast Cancer Study MT
07-16 BriaCell Therapeutics Corp. Opens First Canadian Site For Pivotal Phase 3 Trial In Metastatic Breast Cancer CI
1 day+0.33%
1 week+2.20%
Current month+21.53%
1 month+17.51%
3 months+44.15%
6 months+8.24%
Current year-38.37%
1 week 5.56
Extreme 5.56
6.2
1 month 4.72
Extreme 4.72
6.2
Current year 3.68
Extreme 3.68
16.5
1 year 3.68
Extreme 3.68
20.4
3 years 3.68
Extreme 3.68
1,297.5
5 years 3.68
Extreme 3.68
2,362.5
10 years 3.68
Extreme 3.68
11,250.11
Manager TitleAgeSince
Chief Executive Officer 70 2016-10-31
Director of Finance/CFO 54 2016-01-31
Chief Tech/Sci/R&D Officer 65 2022-02-15
Director TitleAgeSince
Director/Board Member 70 2016-10-31
Chairman 41 2019-04-23
Director/Board Member 74 2019-03-06
Date Insider Type Main position Quantity % Market Cap. Importance
7/7/26 Tax

Director

45,000 0.5173%
7/7/26 Tax

Director

15,000 0.1724%
7/7/26 Option

Chief Financial Officer

28,257 0.3248%
Change 5-day change 1-year change 3-year change Capi.($)
+0.33%+2.20%-59.73%-99.46% 37.17M
-3.30%+1.50%+51.24%+99.26% 72.26B
+1.25%-3.01%+40.12%+77.12% 60.24B
+2.12%+5.26%+32.50%+21.28% 27.73B
-3.06%-1.81%-13.10%+357.06% 25.74B
-0.75%+2.56%+0.45%-4.46% 24.75B
+0.40%+0.75%+22.91%-9.68% 20.74B
-1.70%-2.12%+146.86%+314.52% 15.06B
+0.36%-0.34%+50.32%+166.42% 14.42B
+0.21%+1.17%-8.07%+499.10% 14.23B
Average -0.41%+0.62%+26.35%+142.12% 27.52B
Weighted average by Cap. -0.77%+0.31%+36.30%+129.08%

Financials

2024 2025
Net sales - -
Net income -4.79M -4.2M -3.97M -3.62M -6.77M -459M -6.82M -47.52M -18.4M -235M -17.99M -17.6M -754M -26.31M -23.09M -21.81M -19.87M -37.2M -2.52B -37.47M -261M -101M -1.29B -98.79M -96.65M -4.14B
Net Debt -862K -756K -714K -651K -1.22M -82.63M -1.23M -8.55M -3.31M -42.21M -3.24M -3.17M -136M -17.87M -15.68M -14.81M -13.49M -25.26M -1.71B -25.44M -177M -68.63M -875M -67.08M -65.63M -2.81B
Logo BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Employees
16
Date Price Change Volume
26-09-25 $6.040 +0.33% 10,180
26-09-24 $6.020 +6.36% 12,047
26-09-23 $5.660 -1.39% 2,966
26-09-22 $5.740 -1.03% 9,963
26-09-21 $5.800 -1.86% 5,508

Quarterly revenue - Rate of surprise